Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Aditxt Inc

Announcement: ADTX 10-Q Quarterly Report

Form 8-K - Current report - Item 3.01 Item 9.01

Announcement: ADTX 8-K Special Filing

Form 10-K/A - Annual report [Section 13 and 15(d), not S-K Item 405]: [Amend]

Announcement: ADTX 10-K/A Special Filing Amendment

Form 8-K - Current report - Item 1.01 Item 2.03 Item 7.01 Item 8.01 Item 9.01

ASSET PURCHASE AGREEMENT DATED AS OF APRIL 19, 2023 BY AND BETWEEN THE COMPANY A

FORM OF BUSINESS LOAN AND SECURITY AGREEMENT, DATED APRIL 24, 2023

Form 8-K - Current report - Item 1.01 Item 3.02 Item 8.01 Item 9.01

SHEPPARD, MULLIN, RICHTER & HAMPTON LLP LEGAL OPINION

Part 1: Performance Analysis

Aditxt, Inc. is an innovation company that aims to develop, build, and grow innovations with a focus on monitoring and modulating the immune system. The company has two main programs, which include the immune modulation program and the immune monitoring program. At present, the company's immune modulation technologies are still in the pre-clinical stage and are designed to retrain the immune system to induce tolerance. Meanwhile, its immune monitoring technologies provide personalized comprehensive profiles of the immune system.

From a financial perspective, Aditxt, Inc. had revenues of $0.49 million for the year ended December 31, 2019, an increase of $0.46 million from revenues of $0.03 million for the year ended December 31, 2018. This increase was primarily due to revenues generated from commercializing certain AditxtScore™ proprietary technologies. The company's net loss increased from $16.85 million in 2018 to $44.80 million in 2019, primarily due to an increase in research and development expenses.

The company incurred research and development expenses of $40.71 million in 2019, representing an increase of $26.10 million, compared to $14.61 million in 2018. Aditxt, Inc. expects to continue to incur significant expenses on research and development activities, as it aims to become a leader in the development of innovative immune monitoring and immune modulation products.

Part 2: Future Outlook

The management of Aditxt, Inc. is optimistic about the future prospects of the company, especially with the innovative programs it has developed. CEO Amro Albanna stated that the company is positioned to benefit from the opportunities aligned with addressing immune-related challenges in transplantation, autoimmune, and infectious diseases.

Aditxt, Inc. is banking on its two programs to drive growth in the future. The company plans to conduct further studies for ADI™ in the coming period to evaluate safety/tolerability and efficacy for treating skin allografting, autoimmune diseases, and allergies. The company also plans to conduct a phase I/IIa study for psoriasis, a type-1 diabetes clinical study, and another phase I/IIa study for patients requiring skin allografts.

Furthermore, Aditxt, Inc. plans to launch its AditxtScore™ platform commercially in the second half of 2021. The platform, which provides a personalized comprehensive profile of the immune system, is crucial to developing therapeutics that result in better outcomes for more individuals. The management believes that the platform's broad applicability to many agents of clinical interest will drive growth in the future.

The company is facing stiff competition in the growing and competitive biotech industry. However, the management believes that its innovative portfolio will enable it to be a leader in the development of immune monitoring and immune modulation products. The financial market has shown confidence in Aditxt, Inc., as evidenced by the successful completion of its initial public offering (IPO) in September 2020. The IPO raised approximately $33.6 million in net proceeds, which will provide the company with additional resources to fund its ongoing research and development programs.

Overall, Aditxt, Inc. seems to have a strong outlook for the future, as it continues to develop innovative immune monitoring and immune modulation products. While competition in the biotech industry remains a challenge, the company's proprietary technologies and innovative approach to developing these products will undoubtedly be key in driving growth in the coming years.

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]

CONSENT OF DBBMCKENNON, INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

Announcement: ADTX 10-Q Quarterly Report

Announcement: ADTX 10-Q Quarterly Report

Announcement: ADTX 8-K Special Filing

Announcement: ADTX 8-K Special Filing

Announcement: ADTX 10-K/A Special Filing Amendment

Announcement: ADTX 10-K/A Special Filing Amendment

Announcement: ADTX 8-K Special Filing

Announcement: ADTX 8-K Special Filing

Announcement: ADTX 8-K Special Filing

Announcement: ADTX 8-K Special Filing

Aditxt, Inc.: A promising future in immune system innovations

Aditxt, Inc.: A promising future in immune system innovations